^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

RAPT THERAPEUTICS REPORTS POSITIVE INITIAL DATA FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF FLX475 IN MULTIPLE CANCER INDICATIONS

Published date:
11/16/2020
Excerpt:
Early data from the first two patients with EBV+ lymphoma treated with FLX475 monotherapy show significant target tumor reduction, including one patient (1/2) who achieved a durable complete metabolic response...